Abstract Body

Background: Combination therapy of ribavirin (RBV)+peginterferon (pegIFN) with protease inhibitors for the treatment of HCV is commonly associated with hematologic abnormalities. We sought to analyze immune parameters in patients co-infected with HCV and HIV-1 treated with the 3 direct-acting antiviral (3D) regimen of co-formulated ABT-450 (identified by AbbVie and Enanta)/ritonavir/ombitasvir and dasabuvir given with weight-based RBV. SVR4 rates of 93.5 and 96.9% were observed with 12- and 24-weeks of 3D+RBV therapy in patients co-infected with HCV/HIV-1.

Methods: TURQUOISE-I is a 2-part ongoing, randomized, open-label Phase 2/3 study evaluating the safety and efficacy of 3D+RBV for 12- or 24-weeks in HCV genotype 1/HIV-1 co-infected treatment-naïve or pegIFN/RBV -experienced adults with and without cirrhosis. Laboratory values were assessed at every study visit and post-treatment visit. Treatment-emergent adverse events (AEs) were assessed from the first dose until 30 days after the last dose for any patient who received at least one dose of study drugs.

Results: Hemoglobin decreases were comparable between 12- and 24-week treatment arms (Table). Treatment-emergent anemia was reported in 1 patient in the 12-week arm and in 3 patients in the 24-week arm. RBV dose modification due to decreased hemoglobin occurred in 6 patients (4 in the 12-week arm; 2 in the 24-week arm); all achieved SVR12. No patient had a post-baseline Grade 3 or 4 decrease in hemoglobin. No patient used erythropoietin or received a blood transfusion. Mean absolute CD4+ T cell counts and lymphocytes decreased during treatment and increased to above baseline levels by post-treatment week 12 (Table). CD4 percentages remained stable over time in both treatment arms. No patient had clinically significant abnormalities in platelet or white blood cell counts. Among the 3 patients who experienced a CD4+ T cell count <200 cells/mm3 or CD4+ percentage <14% during treatment, none experienced an AIDS-associated opportunistic infection.

Conclusions: Among HCV/HIV-1 co-infected treatment-naïve and -experienced patients, anemia events were infrequent with 3D+RBV treatment and did not affect treatment outcomes. Transient declines in absolute CD4+ T cells paralleled changes in total lymphocyte count, which is consistent with known hematologic effects of RBV.

viewer?TAG_ACTION=SECURE_FILE_DOWNLOAD&V